


*Sub.  
E. cont*




wherein R is selected from a group consisting of H, alkenyl of 2-8 carbons, alkyl of 1-8 carbons, phenylalkyl of 1-4 carbons, phenyl and COR<sub>2</sub>, wherein R<sub>2</sub> is selected from a group consisting of H, alkyl of 1-8 carbons, alkenyl of 2-8 carbons, phenylalkyl wherein the alkyl has 1-4 carbons (including benzyl) and phenyl, and wherein any phenyl moiety may have up to three substituents selected from the group consisting of hydroxy, carboxy of 1-4 carbons, halo, alkoxy of 1-4 carbons, alkyl of 1-4 carbons, and alkenyl of 2-4 carbons and wherein any alkyl may be a straight chain, branched chain, or the alkyl may be wholly or partially cyclized, said formulation being in the form of a capsule or tablet.

16. (Amended) The composition of claim 15 wherein the composition contains 5-androstene-3 $\beta$ , 17 $\alpha$ -diol.

*D2*  
17. (Amended) The composition of claim 15 in the form of a tablet.

18. (Amended) The composition of claim 15 in the form of a capsule.

19. (Three Times Amended) A composition of matter for inhibiting tumors comprising a tumor inhibiting effective amount of 5-androstene-3 $\beta$ ,17 $\alpha$ - diol or an ester or ether thereof of the formula:



D<sub>3</sub> wherein R is selected from a group consisting of H, alkenyl of 2-8 carbons, alkyl of 1-8 carbons, phenylalkyl of 1-4 carbons, phenyl and COR<sub>2</sub>, wherein R<sub>2</sub> is selected from a group consisting of H, alkyl of 1-8 carbons, alkenyl of 2-8 carbons, phenylalkyl wherein the alkyl has 1-4 carbons (including benzyl) and phenyl, and wherein any phenyl moiety may have up to three substituents selected from a group consisting of hydroxy, carboxy of 1-4 carbons, halo, alkoxy of 1-4 carbons, alkyl of 1-4 carbons, and alkenyl of 2-4 carbons and wherein any alkyl may be a straight chain, branched chain, or the alkyl may be wholly or partially cyclized, in a pharmaceutically acceptable carrier, wherein said 5-androstene-3 $\beta$ ,17 $\alpha$ - diol or ester or ether thereof is part of a cyclodextrin inclusion complex.

D<sub>4</sub> 20. (Amended) The composition of claim 19 wherein the composition contains 5-androstene-3 $\beta$ , 17 $\alpha$ -diol.

Please add the following new claims 21-22:

---

--21. The composition of claim 15, wherein said composition is in a form selected from the group consisting of a spray, a cream, a jelly, a suppository, a douching solution, a liquid, and an adhesive patch.

22. The composition of claim 19 in the form of a tablet.

23. The composition of claim 19 in the form of a capsule.

24. The composition of claim 19, wherein said composition is in a form selected from the group consisting of a spray, a cream, a jelly, a suppository, a douching solution, a liquid and an adhesive patch.--

---